Press releases

September 8, 2022
Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance

January 25, 2022
genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology

June 07, 2021
ERS Genomics and genOway Enter CRISPR/Cas9 Agreement

January 26, 2021
After the United States, the European Patent Office delivers the first European patent for the SMASh technology — and genOway has acquired an exclusive license

January 05, 2021
genOway obtains €2,3M from the European Union and the Auvergne-Rhône-Alpes Region to develop humanized immune checkpoint models

December 01, 2020
genOway and Cyagen have joined forces to form a long-term strategic partnership in the Asia-Pacific region

January 07, 2020
genOway and Merck strengthen CRISPR/Cas9 strategic alliance by extending their partnership to all animal cell models

October 30, 2019
The Institut Pasteur and Cellectis extend exclusive license rights by granting genOway the authority to take action against infringement

June 4, 2019
genOway announces the consolidation of a precompetitive consortium to develop and validate humanized immune checkpoint mouse models

May 27, 2019
genOway licenses the Flex technology rights to HHMI for the distribution of its AAV FLEX

December 10, 2018
Merck and genOway form CRISPR/Cas9 strategic alliance to develop rodent models

September 25th, 2018
genOway announces the acquisition of Axenis to create the largest offer of preclinical models in the Immuno-oncology and Immuno-inflammation space